Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNFα inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial
RCT (n=381) reports ACR20 at week 24 was achieved by significantly greater proportions of patients in the guselkumab every 4 weeks group (59%) and every 8 weeks group (52%) than in the placebo group (22%) [differences vs placebo of 37% and 30% respectively, both p<0.0001].
Source:
The Lancet
SPS commentary:
A separate publication describes the outcomes for guselkumab use in biologic-naïve patients with active psoriatic arthritis - DISCOVER-2.
In a related editorial, authors highlight that the major limiting factor influencing the interpretation of the results of both studies is the typical selective population investigated, without the frequent multimorbidity profile of patients that are typically seen clinically with psoriatic arthritis.